Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Non-cash Items (2016 - 2026)

Anika Therapeutics has reported Non-cash Items over the past 13 years, most recently at $1.7 million for Q1 2026.

Quarterly Non-cash Items changed N/A to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, changed N/A year-over-year, with the annual reading at $1000.0 for FY2025, N/A changed from the prior year.
Non-cash Items was $1.7 million for Q1 2026 at Anika Therapeutics, up from $1000.0 in the prior quarter.
Over five years, Non-cash Items peaked at $1.7 million in Q1 2026 and troughed at $1000.0 in Q2 2025.
The 5-year median for Non-cash Items is $157500.0 (2023), against an average of $331928.6.
Year-over-year, Non-cash Items surged 6922.22% in 2023 and then crashed 99.67% in 2025.
A 5-year view of Non-cash Items shows it stood at $1.0 million in 2022, then tumbled by 87.9% to $127000.0 in 2023, then skyrocketed by 95.28% to $248000.0 in 2024, then plummeted by 99.6% to $1000.0 in 2025, then surged by 166500.0% to $1.7 million in 2026.
Per Business Quant, the three most recent readings for ANIK's Non-cash Items are $1.7 million (Q1 2026), $1000.0 (Q4 2025), and $1000.0 (Q2 2025).